Article Sidebar

PDF
Date Published: 12/04/2023
Abstract Views: 126
Views PDF: 105
DOI: https://doi.org/10.51298/vmj.v525i1A.4988
Issue
Vol. 525 No. 1A (2023)
Section
Các bài báo
How to Cite
Nguyễn, T. L. ., & Lê, N. H. . (2023). THE BLOOD GLUCOSE DISORDERS OF SEVERE AND CRITICAL ILL COVID-19 PATIENTS AT COVID-19 PATIENTS TREATMENT HOSPITAL HA NOI MEDICAL UNIVERSITY HOSPITAL. Vietnam Medical Journal, 525(1A). https://doi.org/10.51298/vmj.v525i1A.4988

THE BLOOD GLUCOSE DISORDERS OF SEVERE AND CRITICAL ILL COVID-19 PATIENTS AT COVID-19 PATIENTS TREATMENT HOSPITAL HA NOI MEDICAL UNIVERSITY HOSPITAL

Thùy Linh Nguyễn1,, Ngọc Hà Lê1
1 Hanoi medical university

Main Article Content

Abstract

The study was conducted on 460 severe and critical ill COVID-19 patients in the COVID-19 treatment hospital from September 2021 to the current day with two objectives: describing the blood glucose disorders of inpatients at three different times: the first 24-48 hours of admission, during the treatment ad ward, the discharge day and investigate some associated factors between the condition of glucose disorders and patient outcomes. The results show that COVID-19 patients have a higher percentage of suffering from glucose disorders than other patients (88.41% and 71.62%). Some associated factors that can be related to the glucose disorders of patients include types of oxygen support and propofol usage. The variation of blood glucose results of patients in treatment time and discharge day is associated with the patient outcomes.

Article Details

Keywords

the blood glucose disorders, Capillary blood glucose, COVID-19, ICU.

References

1. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020; :e3319.
2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020; 323:1239.
3. Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol 2020; 14:813.
4. Riddle MC, Buse JB, Franks PW, et al. COVID-19 in People With Diabetes: Urgently Needed Lessons From Early Reports. Diabetes Care 2020; 43:1378.
5. Elamari S, Motaib I, Zbiri S, et al. Characteristics and outcomes of diabetic patients infected by the SARS-CoV-2. Pan Afr Med J. 2020 Sep 8;37:32. doi: 10.11604/pamj.2020. 37.32.25192. PMID: 33209159; PMCID: PMC7648481.
6. Singh AK, Gupta R, Ghosh A, et al. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020 Jul-Aug;14(4):303-310. doi: 10.1016/j.dsx.2020.04.004. Epub 2020 Apr 9. PMID: 32298981; PMCID: PMC7195120.
7. Chen, Y, Gong, Wang L, Guo J. "Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. medRxiv 2020; published online March 30." DOI 10, no. 2020.03 (2020): 25-20043133.
8. CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 3;69(13):382-386. doi: 10.15585/mmwr.mm6913e2. PMID: 32240123; PMCID: PMC7119513.